We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Internal Medicine

Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD

MedXY Editorial Team•Feb 23, 2026•Internal Medicine
Clinical Prediction ModelsCOPDfall preventiongeriatric medicine

Highlights

Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic condition where fall risk is significantly elevated, yet accurate prediction remains a challenge. A recent study has established a clinical prediction model with the following key findings:

  • Approximately 42% of individuals with COPD experienced at least one fall over a 12-month prospective period.
  • The final predictive model identified three robust factors: a history of two or more falls in the preceding year, a higher number of chronic conditions, and poor performance on the Timed Up and Go Dual-Task (TUG-DT) test.
  • A history of recurrent falls (≥2) was the strongest predictor, increasing the odds of future falls by more than 3.5 times.
  • The model demonstrated acceptable discrimination (c-statistic 0.69) and excellent calibration, providing a foundation for clinical screening.
MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Astegolimab for Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Insights from the Pooled ALIENTO and ARNASA TrialsAstegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with gSep 13, 2026Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 AnalysisDupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.Sep 12, 2026Defining and Achieving Disease Stability in COPD: Insights from Phase 3 TrialsThis article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.Sep 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
Aug 23, 2026
Refining COPD Exacerbation Risk Categories Enhances Prediction of Future EpisodesA recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.Aug 20, 2026
Unraveling the Mortality Benefits of Beta-Blockers in COPD Patients with Cardiovascular Disease: Influence of LABA Co-therapyA large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.Aug 12, 2026